StockData
ADC Therapeutics SA logo

ADC Therapeutics SA (ADCT) stock

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$1.35+0.10 (+8.00%)

Close on Nov 17, 2026Market cap $172.35MP/E –Yield –

ADC Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

ADC Therapeutics's price to sales ratio was 2.6× on Nov 11, 2026, against 6.4× a year earlier. Over the last 5 years it ranged from 0.3× to 91.7×, with a median of 3.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.6×−2.7
2025Dec 31, 20255.3×+2.6
2024Dec 31, 20242.7×+1.6
2023Dec 29, 20231.1×−0.8
2022Dec 30, 20221.9×−89.8
2021Dec 31, 202191.7×–

More ADC Therapeutics figures

See a number that looks wrong?